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ABSTRACT 
APOBEC3 proteins are cytidine deaminases that are potent inhibitors of retrovirus 
replication. These restriction factors induce G→A hypermutation as a result of deamination of 
cytidine in the single stranded transcripts generated by reverse transcription during replication. 
Mouse APOBEC3 (mA3) effectively inhibits the replication of endogenous retroelements 
whereas most exogenous murine leukemia viruses (MuLV) are largely resistant to the action(s) 
of mA3. However, several studies have reported significant inhibition of infectivity by virion-
associated mA3 that did not appear to be the result of G→A hypermutation. In this report the 
influence of different levels of virion-associated mA3 on the exogenous MuLV, CasFrKP was 
examined. A correlation was observed between the level of incorporated mA3, the virion specific 
infectivity, the virion reverse transcriptase (RT) activity and the mutation frequency. Although 
G→A hypermutation of CasFrKP was not observed, the frequency of other transition mutations 
was significantly increased. G→A mutations induced by mA3 have been reported to exhibit a 
strong consensus of two bases flanking the mutation. No strong consensus was observed for 
mA3-induced mutations of CasFrKP suggesting a general decrease in the fidelity of the RT. The 
results of this study strongly suggest an interaction between mA3 and the RT of CasFrKP leading 
to a loss of activity as well as fidelity of the polymerase that ultimately results in a significant 
loss of infectivity. 
In contrast to CasFrKP, AKV, an ecotropic MuLV isolated from AKR mice, has been reported to 
undergo hypermutation mediated by mA3. In this report we also confirm that AKV does undergo 
G→A hypermutation upon infection of 3T3 cells, however hypermutation is not augmented in 
viruses that have incorporated HA-tagged mA3. Furthermore, the observed G→A transition 
mutations are not randomly distributed in that multiple mutations frequently occur in a single 
iii 
 
transcript. These observations suggest that the G→A mutations are the result of the incorporation 
of an unknown restriction factor in only a portion of the released virions. 
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Chapter 1: Introduction 
1.1. Retroviruses 
Retroviruses are enveloped RNA viruses that include different sub-families. They are 
termed retroviruses because of their means of replication. The viral genome is a linear RNA 
molecule that, upon infection is transcribed from RNA to linear double-stranded DNA, a process 
that is termed reverse transcription. The double-stranded DNA is subsequently integrated into the 
genome of the host cell (72). If this occurs in a germline cell the retrovirus becomes a permanent 
component of the host genome that is passed down to subsequent generations (129). Over the 
course of evolution, the human genome has been infected approximately 40,000 times such that 
about 10% of the genome consists of retroviral sequences (129). 
Among the retrovirus family we find important pathogens such as HIV-1, feline leukaemia virus, 
and several cancer-causing viruses (72). Various retroviruses have been found that infect a large 
number of organisms, including humans and many other mammals. The earliest retroviruses 
studied were isolated from mice and birds. Examples of such retroviruses include murine 
leukemia virus (MuLV), mouse mammary tumor virus (MMTV), and the avian pathogens Rous 
sarcoma virus (RSV), spleen necrosis virus (SNV), and avian leukosis virus (ALV) (14). 
The viral RNA is made up of two identical RNA genomes that are incorporated into the virion 
and are comparable to a large polycistronic messenger RNA (67). Reverse transcription of the 
viral RNA results in the generation of DNA transcripts which are ultimately integrated into the 
target cell genome as a provirus (129). Once integrated, the provirus is able to employ the cell's 
transcriptional machinery to transcribe its genome into full-length genomic RNA, which also 
serves as a messenger RNA (129). A portion of the full-length RNA is spliced into a shorter 
RNA that is translated to yield the Env proteins while the full-length RNA is translated into the 
2 
 
remaining structural proteins of the virus as well as the viral polymerase. The translated proteins 
and full-length genomic RNA are assembled to create new retroviruses that are subsequently 
released from the cell through budding. Non-defective viruses are capable of infecting new cells. 
 
1.2. Murine Leukemia viruses 
Murine leukemia viruses (MLVs or MuLVs) are retroviruses originally named for the 
ability of some members of the group to cause tumors in murine hosts. Some MuLVs may infect 
other vertebrates, including humans, and have been implicated in the induction of leukemias in 
gene therapy patients (49). MuLVs include both exogenous and endogenous viruses and are 
classified in the Baltimore classification of viruses as Type VI (+) belonging to the 
Gammaretroviral genus of the Orthoretroviridae subfamily, Retroviridae family. The viral 
particles (Figure 1) of replicating MuLVs have what is termed a C-type morphology as 
determined by electron microscopy (8), with a diameter of ∼100–120nm (149) and a spherical 
inner core composed of the nucleocapsid (NC) and capsid (CA) proteins (8,133). Inside the core 
there are: RNA genome, reverse transcriptase (RT), integrase (IN), protease (PR), and the 
tRNAPro primer (67). 
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Figure 1. Structure of a MuLV particle. TM and SU subunits are located at the outer surface of the virus, 
while the inner part of a virion, known as the core, contains the RNA genome, NC, IN and PR surrounded 
by the CA. The CA is surrounded by the p12 and the MA protein, which helps anchor the lipid membrane. 
Figure credit: Dr. Leonard Evans. 
 
The virus is encapsulated in a lipid envelope that is coated with glycoprotein spikes similar to 
that of the human immunodeficiency virus (HIV) (111). The spikes consist of the glycoprotein 
SU (surface) which includes regions binding the cellular receptor and determines the host range 
of the virus and the TM (transmembrane) protein, which anchors the SU protein to the virion by 
disulfide bridges. The TM protein is involved in fusion of the viral membrane to cellular 
membrane. In contrast to other types of retroviruses, type C particles appear to be assembled 
largely at the plasma membrane during budding. 
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MuLVs can be transmitted from one host to another by horizontal transmission of exogenous 
viruses or transmitted from parent to offspring by vertical transmission of endogenous MuLVs 
integrated into the host genome (67). The major classification of MuLVs has been based on host 
specificity or tropism which reflects different cell-suface receptor usage. Focusing on this type of 
classification we can distinguish between ecotropic (77) MuLVs that infect only mice, and utilize 
the mCAT-1 receptor (4); amphotropic MuLVs that infect mice and cells of many other species 
using the Pit-2 receptor (52,144); xenotropic MuLVs, that are endogenous to mice, can infect 
cells of many species but do not infect mouse cells, and utilize the Xpr-1 receptor (77), and 
polytropic viruses that can infect many species including mice and humans and also use Xpr-1 as 
a receptor (139). 
MuLVs are comprised of a large number of mouse gammaretroviruses. Some MuLVs that cause 
proliferative diseases in mice are named after their discoverers: Gross MuLV by Dr. Ludwig 
Gross (lymphocytic leukemia) (47); Graffi MuLV by Dr. Arnold Graffi (erythroleukemia) (42); 
Friend MuLV (F-MuLV) by Dr. Charlotte Friend (erythroleukemia) (41); Moloney (M-MuLV) 
by Dr. John B. Moloney (lymphocytic leukemia) (87); Rauscher MuLV (R-MuLV) by Dr. Frank 
J. Rauscher (erythroleukemia) (110); Kirsten MuLV (Ki-MuLV) by Dr. Warner H. Kirsten 
(lymphocytic leukemia) (66); and Abelson MuLV (A-MuLV) by Dr. Herbert T. Abelson (B-cell 
leukemia) (1). 
 
1.3. MuLV Genome and Proteins 
Viral genomic RNAs resemble large mRNAs (~8.3 kb) containing a 5' cap (113) and are 
polyadenylated at the 3' end (45). The RNA genome begins with a 5’ short terminal repeat, R 
(53,125), followed by a short region which is termed U5 (61). Near the 3’ terminus of the viral 
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genome is a region termed U3 region, which contains the transcriptional regulatory elements of 
the virus (20). The U3 is followed by the 3’ short terminal repeat (R) (53). The U3 region and U5 
region are so named because they are unique 3’ and 5’ sequences that are incorporated along with 
the R region into the long terminal repeat (LTR) found in proviral DNA after reverse 
transcription (Fig. 2). 
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Figure 2. MuLV genomic structure and organization. The proviral DNA is flanked by two LTRs, both of 
which contain a U3, R and U5 region. Following the 5' LTR are signals that function in primer binding 
(PBS), splicing (SD), dimerization of the RNA genome (DLS), and packaging (psi). Next are the genes that 
code for internal structural components (Gag), replication (Pol) and receptor recognition (Env). These are 
followed by a sequence required for DNA synthesis (PPT) and an LTR which contains transcriptional 
regulatory sequences. Transcription of proviral DNA into RNA ( ) leads to two major species, the full-
length genome, and the spliced mRNA that encodes the envelope polyprotein. Translation of the full-
length RNA yields the polyproteins ( ) gGag, Gag and Gag-Pol. Translation of the spliced mRNA yields 
the Env polyprotein. These polyproteins are further processed by the viral protease ( ) to yield their 
mature forms. 
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Three major polyproteins are encoded by the MuLV genome. The Gag polyprotein is comprised 
of the major structural components of the viral core and includes the hydrophobic matrix protein 
(MA, p15gag) (6), the acidic phosphorylated protein (pp12) (98), the neutral capsid protein (CA, 
p30) (97), and the basic nucleocapsid protein (NC, p10) (40). The Pol polyprotein is comprised 
of the protease (PR, p14) (100), the reverse transcriptase (RT, p80) (5), and integrase enzymes 
(IN, p46) (43). The Env polyprotein encodes the surface glycoprotein (SU, gp70env) (59) and 
transmembrane proteins (TM, p15env) (61) that jointly mediate the entry of an infectious virus 
particle into a new host cell to initiate infection (127). Many gammaretroviruses, including M-
MuLV and F-MuLV, as well as feline leukemia virus, encode an additional glycosylated form of 
the Gag protein termed glyco-Gag (36). “glyco-Gag” or gPr80Gag differs in sequence from 
“standard” Gag in that it is contains additional N-terminal amino acids. Synthesis of glyco- Gag 
is initiated at a CUG codon in a favorable context for translation initiation, 264 bases 5’ of the 
normal Gag AUG initiation codon (108,36). 
As in all orthoretroviruses, the three coding regions are organized, from 5’ to 3’, gag, pol and 
env. The Pol proteins are firstly synthesized together with Gag, in a large Gag-Pol merged 
polyprotein. Gag and Gag-Pol are both translated from full-length viral RNA, identical in 
sequence to the genomic RNA present in the virion. It seems likely that the Gag-Pol polyprotein 
is incorporated into assembling virions due to “coassembly” of its Gag moiety with Gag 
polyprotein molecules (37). In the gammaretroviruses such as MuLV, gag and pol are in the 
same reading frame, divided by a single termination codon. MuLV RNA contains a 57-base cis-
acting signal immediately 3’ of the termination codon (38) that induces the insertion of glutamine 
(normally encoded by CAG), rather than UAG codon termination in about 5% of the translation 
products. The resulting product is extended by translation of the entire Pol coding region (153). 
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The Env protein of MuLV, like that of other orthoretroviruses, is translated from a singly spliced 
mRNA. There is an overlap of 58 bases between the end of the Pol coding region and the 
beginning of the Env coding region (111). 
There are noncoding regions in the MuLV RNA that contains a set of cis-acting signals that are 
essential for its function as a viral genome. These include the “primer binding site” (PBS), the 
polypurine tract (PPT) which is necessary for second strand synthesis of DNA and participates in 
the insertion of the DNA form of the viral genome into cellular DNA by the IN protein, the 
“packaging signal” sequences (Ψ, psi) required for packaging of the viral RNA into virions, and 
the promoter and enhancer sequences within the LTR. The PBS is an 18-base stretch that is 
complementary to the last 18 bases of a cellular tRNA molecule. In exogenous MuLVs, this is 
usually tRNAPro, however endogenous MuLVs frequently utilize tRNAGlu. Within the virion, the 
tRNA is hybridized to the viral RNA and upon infectious entry, the tRNA serves as the primer for 
reverse transcription. The PBS is located ∼145 bases from the 5’ end of the RNA and ∼460 bases 
5’ of the start of the Gag coding region (111).  
In general, during reverse transcription the RNA is copied by the polymerase activity of RT and 
is progressively degraded, shortly after being copied, by the RNase H activity of RT. However, 
an exceptional stretch of ∼15 purines near the 3’ end of retroviral RNAs (the PPT) is specifically 
resistant to this degradation. After reverse transcription, this fragment of the viral RNA serves as 
the primer for synthesis of the second (plus) strand of DNA. The 3’ terminal base of the PPT 
encodes the first base of the plus strand of the DNA copy, that is, the 5’ end of the plus strand or 
“left” end of the double-stranded DNA (111). These sequences at the two ends of the final DNA 
product are the sequences joined by IN to host-cell chromosomal DNA during the integration 
reaction (12).  
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Between the PBS and the packaging signal (psi) there is the splice donor (SD) site (126) that is 
joined to a splice acceptor (SA) site that precedes the env gene. The spliced env gene mRNA 
lacks the packaging signal and thus avoids packaging into the virion. The psi region also contains 
the dimer linkage site (DLS) that is required for RNA dimerization (89,117). In all 
orthoretroviruses, the viral RNA is actually packaged in dimeric form, with two molecules of the 
viral RNA linked by a limited number of intermolecular base pairs. The primary location of these 
base pairs is in the “leader”, between the PBS and the beginning of the Gag coding sequence 
(69). 
1.4. Replication Cycle 
1.4.1. Binding and entry 
As with all orthoretroviruses, infection is initiated by the binding of the SU (gp70) 
glycoprotein on the exterior of the mature, infectious virion to a receptor on the surface of the 
target cell (56). This binding event triggers dramatic changes in Env, leading to the release of the 
SU component and conformational rearrangement of TM. The ultimate result is the fusion of the 
viral membrane with a cellular membrane. In some cases, fusion may occur within endosomes 
that have captured virions (85). The fusion of the two membranes leads to the deposition of the 
contents of the virion in the cytoplasm of the cell (67). The replication cycle of MuLV is depicted 
in Fig. 3. 
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Figure 3. Replication cycle of MuLV. 1) Envelope glycoproteins bind to the specific cell receptors required 
for viral entry. 2) Fusion and entry into the cell. 3) Uncoating of virion 4) Reverse transcription. 5) 
Preintegration complex enters nucleus, integrates proviral DNA into host genome. 6) Transcription of 
provirus. 7) Translation of virion components. 8) Assembly at the cell membrane. 9) Budding of the virion. 
10) Maturation and release of the virion. 
 
1.4.2. Reverse transcription and integration 
After fusion of the virion with the cellular membrane, the viral capsid uncoats and the 
RNA genome is reverse transcribed into DNA (Fig. 4). Reverse transcription may proceed as 
soon as intact capsids have access to nucleotides following fusion (72). The provirus is 
synthesized from the RNA genome by the virion reverse transcriptase (RT). At the beginning of 
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the process the tRNApro, which is carried into the virion, binds the primer binding site of the viral 
RNA (53) and the RT begins to transcribe the cDNA in the 3' to 5' direction ending at the R 
region (53). At the same time, the RNase H activity of RT degrades the RNA portion of the 
RNA/DNA Hybrid (44). The complementary DNA just formed, termed strong stop DNA, then 
binds to the 3’ complementary R region at the end of the viral RNA (23,24). The first strand of 
complementary DNA (cDNA) is extended and the majority of viral RNA is degraded by RNAse 
H except for the PPT region (32). This region is then used as a primer by RT to synthesize the 
plus strand DNA in 5’ to 3’ direction, using as a template the cDNA (131). The RNase H 
removes the primer tRNA, exposing sequences in +DNA that are complementary to sequences at 
or near the 3′end of plus-strand DNA. Annealing of the complementary PBS segments in +DNA 
and minus-strand DNA constitutes the second strand transfer. Plus and minus-strand syntheses 
are then completed, with the plus and minus strands of DNA each serving as a template for the 
other strand (71,22). 
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Figure 4. Schematic description of Reverse transcription 1). The tRNAPro binds to the PBS of the RNA 
genome 2). RT transcribes minus (-) strand DNA in the 3' to 5' direction ending at the R region. 3). RT's 
RNase H activity degrades the RNA portion of the RNA/DNA hybrid. 4). The newly synthesized DNA and 
tRNA primer dissociates from the 5' end of the RNA genome and hybridizes to the 3' R region of the 
genome. 5).Minus strand DNA synthesis continues to the PBS at the 5' end of the molecule. 6). RNase H 
activity of RT degrades the RNA genome, except for the PPT region. 7). RT uses the PPT RNA as a primer to 
synthesize (in the 5' to 3' direction) the plus (+) strand of DNA to the PBS contained within the strong stop 
(-) DNA, using the minus strand as a template. The resultant strand is called strong stop plus (+) strand 
DNA. 8). The tRNAPro primer, PPT RNA and all remaining RNA are removed. The PBS of the (+) strand can 
anneal to the PBS of the minus strand and RT can further synthesize DNA 9). Resulting in a double 
stranded proviral DNA genome. 
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After reverse transcription is complete, the resulting double stranded DNA transcript is 
associated with cellular and viral proteins into a preintegration complex (PIC) that is 
subsequently translocated to the nucleus (Fig. 5). MuLV PICs are translocated upon 
disintegration of the nuclear membrane during mitosis while PICs of HIV and other lentiviruses 
are actively translocated through pores in the nuclear membrane (30). Insertion of the viral DNA 
into the host cell DNA is catalyzed by a viral enzyme called integrase (IN). This enzyme 
recognizes and nicks the two ends of viral DNA, and the new 3′-ends are then joined covalently 
to the host DNA at staggered nicks made by integrase. Although retroviruses may integrate at 
many different sites in the genome, the process is not entirely random. MuLVs exhibit 
preferential integration sites near transcriptional start sites and are influenced by MuLV Gag and 
IN proteins, while lentiviruses exhibit preferential integration within actively transcribed gene 
sequences (30). Once the preintegration complex associates with the host chromosome, viral IN 
catalyzes the insertion of the viral sequences into the host DNA. The two LTR ends of the linear 
viral DNA are brought together into a ternary complex with IN and host DNA, where the 
insertion occurs in a coordinated or concerted reaction (58). A 2-bp sequence is lost from each 
end of the viral DNA, and a short duplication of 4 to 7 bp from the host, depending upon the 
viral IN, is introduced into the host sequence flanking the viral DNA. Integrated viral DNA is 
termed the provirus (58). Integration occurs in two well-characterized catalytic steps, referred to 
as end processing and joining, respectively. End processing involves removal of a dinucleotide, 
adjacent to a highly conserved CA dinucleotide, from the 39 bp strand of the U3 and U5 viral 
DNA LTRs in a reaction involving a water molecule or other nucleophile. This exposes a 
hydroxyl group, whose oxygen is used as an attacking nucleophile on the target DNA during the 
joining reaction, in which the viral DNA is inserted into the cellular DNA (58).  
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Figure 5. Integration of proviral DNA. 1). The proviral 
cDNA (in blue) is bound to the integrase portion of 
the pre-integration complex (PIC). 2). The 3' ends of 
the DNA are nicked by IN to produce 3' hydroxyl 
ends. 3). The PIC is then shuttled into the nucleus 
and the IN produces a 4-6 bp staggered cut in the 
host genome (in black) which acts as a target for the 
proviral genomes free hydroxyl groups to integrate 
into. 4). The pairing of host DNA is dissolved. 5). The 
gaps left behind and the non-complementary ends 
of the proviral genome are 6). repaired and 
removed, respectively. 
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1.4.3. Transcription of the provirus 
Once the viral DNA is integrated into host DNA, it is transcribed and translated by 
normal host-cell machinery (111). Specifically, the provirus is transcribed as a cellular gene by 
RNA polymerase II and mediated by transcriptional control elements contained within the 
proviral LTR (48). Expression directed by the viral LTR signals is carried out entirely by host 
cell enzymes (RNA pol II, poly A synthetase, guanyl transferase). The enhancer and other 
transcription regulatory signals are contained in the U3 region of the 5' LTR, and the TATA box 
is located roughly 25 bp from the beginning of the R sequence. The integrated provirus has two 
LTRs, and the 5' LTR normally acts as an RNA pol II promoter (48,27). The transcript begins, at 
the beginning of R, and proceeds through U5 and the rest of the provirus, usually terminating by 
the addition of a poly A tract just after the R sequence in the 3' LTR (48). The mRNA generated 
during the transcription can be spliced or unspliced and then translated to produce the viral 
proteins. 
1.4.4. Translation and maturation 
Cells infected by a retrovirus synthesize virus-specific RNAs by transcription of the 
integrated proviral DNA. The primary transcript is 5’ capped and 3’ polyadenylated and can be 
either spliced to give the subgenomic RNAs or transported to the cytoplasm where it serves as an 
mRNA for the synthesis of gag and gag-pol polyproteins and/or as the pregenomic RNA. The 
gag and gag-pol polyproteins are the precursors to the major proteins and enzymes, respectively, 
of the virion core (21). The genetic organization of the 5’ sequences of the genomic RNA is 
complex and contains a long multifunctional 5’ untranslated domain, the leader, that precedes the 
gag gene. The 5’ leader is formed of independent well structured domains involved in key steps 
of the viral life cycle such as the initiation of proviral DNA synthesis (the PBS and R sequences), 
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genomic RNA dimerization and encapsidation (the dimerization-encapsidation signal E/DLS), 
and the initiation of gag precursor translation (AUG-619 gag initiation codon). The genomic 
RNA of MuLVs directs the synthesis of two gag-related proteins: Pr65gag, the precursor to the 
virion core structural proteins, and Pr75glyco-gag, the precursor to the glycosylated gag protein 
found on the surface of MuLV-infected cells (36,121). Translation of Pr65gag starts at an AUG 
while Pr75glyco-gag is initiated at a CUG located within the 5’ leader and in frame with AUGgag. 
(108). During virus maturation Pr65gag is proteolytically cleaved into the final products 
designated p15, pp12, p30, and p10 (176). The processing is accomplished by a virion-associated 
protease (150), which first cleaves Pr65gag into Pr27gag (p15 + pp12) and Pr40gag (p30 + p10), the 
two major intermediate cleavage products (145,151). The MA protein (p15) is the most 
hydrophobic protein of the virus (6). The CA protein (p30) is neutral and is the major structural 
protein of the virus (96). Bound to the genomic RNA is the basic nucleocapsid protein (NC or 
p10) which is a major component of the ribonuclear protein complex (40).  
The Gag-Pol polyprotein, in addition to Gag includes PR, RT, and IN. The PR protein (p14) 
catalyzes the cleavages leading to virus maturation. Like all retroviral PRs, it is an aspartic 
protease, which is only active as a dimer (84,138). RT (p80) is packaged into the core of the 
virion and synthesizes the DNA copy of the viral genome during infection. MuLV RT is active as 
a monomeric protein (28,86). MuLV IN (p46) is also incorporated into the core of the virion and 
has not been characterized in detail but is presumed to function as a tetramer (142,51). 
The MuLV Env gene product is synthesized in the rough endoplasmic reticulum and 
glycosylated in the Golgi apparatus. It is also cleaved in the Golgi by a cellular furin-like 
protease into two fragments, the large, N-terminal surface glycoprotein (SU or gp70) and the C-
terminal transmembrane protein (TM or p15E). A trimer of these heterodimeric SU-TM 
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complexes is then trafficked to the cell surface. Once the envelope protein has reached the cell 
surface, it is incorporated into a budding C-type retroviral particle (57, 124). SU and TM proteins 
are linked through a labile disulfide bond (103,105) with the SU on the outside of the particle 
and the TM exhibiting an extraparticle domain, a transmembrane domain, and a 35-amino acid 
domain that resides within the particle (104). During a late stage of viral particle maturation the 
carboxyl-terminal 16 amino acid residues of the TM protein are removed by the retroviral PR 
resulting in a 12-kDa envelope transmembrane protein (135,127,57,26,64,124). The Env protein 
present on the membrane of an infected cell is therefore structurally different from that found in 
a mature particle. Removal of the carboxyl-terminal region during maturation activates the Env 
protein so that it is capable of fusing membranes in a receptor-dependent manner (109,112,141). 
The immature virion particles are released from the host cell through a budding mechanism and 
subsequently undergo maturation as the PR in the virus cleaves the viral polyproteins. 
1.5. Restriction Factors 
Over the course of the retroviral replication cycle, viral cDNA is introduced into host 
chromosomal DNA to establish the provirus. If this occurs in a germline cell the process results 
in a permanent insertional mutation in the host cell genome. In this regard approximately 10% of 
the human and mouse genomes are derived from retroviruses that have been inserted over the 
course of evolution (129). Host cells have evolved intracellular factors that block the spread of 
retroviral infection. Some of these antiviral factors act prior to integration and therefore also 
block the mutagenic potential of infection. Several such factors have been identified, including 
Fv1, the APOBEC3 complex, and TRIM5. These host factors potently block HIV-1 and other 
retroviruses from establishment of the provirus (72). 
Fv1 restriction was the first system for resistance to MuLV to be described in mice. Fv1 confers 
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resistance to MuLVs, blocking progression of the viral life cycle after reverse transcription, but 
before integration into the host chromosome. It is known that the specificity of restriction is 
determined by both the restriction factor and the viral capsid CA (78,63,137). Identification of 
the Fv1 gene as an endogenous virus-derived gag gene has led to speculation that its gene 
product may interact with the Gag proteins of an infecting MuLV preventing a crucial interaction 
necessary for efficient infection. However a direct interaction between Fv1 and MuLV CA has 
not yet been demonstrated (134).  
The human gene encoding an activity similar to Fv1 was originally called Ref1 and is now 
known as TRIM5α (55,65,101,148). TRIM5α is a member of the tripartite motif (TRIM) protein 
family, TRIM5α binds to the retroviral capsid lattice in the cytoplasm of an infected cell and 
accelerates the uncoating process of retroviral capsid, thus providing a potent restriction to HIV-
1 and other retrovirus infections (29). Another restriction factor called tetherin (CD317/BST-2) 
blocks the release of viral budding particles from the cell membrane by tethering newly forming 
viruses to host cells (54,76). 
1.5.1. APOBEC3 
APOBEC3 (Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3) 
proteins are a sub-family of intrinsic restriction factors of the innate immune system (25). They 
are able to block retroviruses from different species after the entry into the host cells (75). 
APOBEC3 proteins were originally discovered by Sheehy et al. in 2002 during their 
investigations of the HIV-1 (18). In this study they observed that when the Vif gene is removed 
from HIV-1, the resulting HIVΔvif viruses do not produce infectious particles in some cells (Fig. 
6) (18). Their studies concluded that there were cellular factors acting against HIV-1 that could 
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inhibit the infectious cycle of the virus in the absence of the vif protein (18). It was subsequent 
discovered that the human APOBEC3G (hA3G) was a target of the Vif protein. 
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Figure 6. APOBEC3 activity. hA3G-mediated restriction of HIV-1Δvif. hA3G proteins are incorporated into 
the budding particles during assembly at the cellular inner membrane, after the first round of infection. 
hA3G is able to inhibit the replication cycle of the retroviral pathogens during the second round of 
infection. Restriction of retroviral pathogens is mediated by deamination-dependent and –independent 
restriction pathways of the protein. Figure credit: Chiu and Greene. 2008 
 
APOBEC3 proteins possess enzymatic activity that targets single-stranded DNA. They 
deaminate cytidines to uridines, disrupting the single-stranded DNA sequences and ultimately 
induce guanosine to adenosine hypermutation of the proviral genome (18,90). Since the reverse 
transcription of the viral genomic RNA occurs in the host cell cytoplasm, retroviral DNA 
intermediates become a major target for APOBEC3 proteins (3,18,90). 
Different studies revealed that humans have seven APOBEC3 genes (A3A, A3B, A3C, A3DE, 
A3F, A3G and A3H) all of which are located within a 150kb region on chromosome 22 
(318,90,93). The feline genome has four A3 genes, the equine genome has six, and the mouse 
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genome has only a single copy of the A3 gene (75,114). Human A3A, A3C, and A3H proteins 
contain one catalytic domain (CD). In contrast A3B, A3DE, A3G, and A3F and the mouse A3 
protein have two catalytic domains (3,18,60,74,90). The most extensively studied member of the 
APOBEC3 family is the hA3G protein because of its potency as an antiretroviral restriction 
factor and its importance for HIV-1 infection. hA3G is incorporated into virions and acts through 
cytidine deamination of single stranded DNA during reverse transcription. The inhibitory activity 
of hA3G is dependent on two catalytic domains (CDs). CD1 mediates RNA binding and 
incorporation into the virion (15) and the C-terminal (CD2) domain catalyzes deamination (91). 
Encapsidation of hA3G requires the nucleocapsid (NC) region of HIV-1 Gag (136), and as few 
as 7 APOBEC molecules incorporated into a HIV-1 ∆Vif virion are sufficient to inhibit the virus 
in the next round of infection (146). 
After the entry in uninfected cells, the viral particles containing hA3G are uncoated and the the 
viral capsid is liberated into the cytoplasm of the cell. The reverse transcription process starts 
with the elongation of tRNA attached to the viral genomic RNA, allowing for the production of 
the minus strand strong-stop DNA. The strong-stop DNA is translocated to the 3’ end to generate 
the whole minus strand (153) where hA3G acts to deaminate cytidines to uridines. The mutation 
rates of these sequences increase with longer exposure time to A3 proteins. Therefore, the 
number of mutations are directly related with the exposure time prior to plus strand DNA 
synthesis and the distribution of mutations is skewed (153). DNA strands containing uridine may 
be degraded by uracil DNA glycosylase and apurinic-apyrimidinic endonuclease (147). Strands 
that are not degraded and serve as a template for plus-strand synthesis incorporate A residues 
rather than G residues at the deaminated positions. Extensive G-to-A mutations render the 
provirus inactive. Unfortunately, retroviruses such as HIV-1 have evolved mechanisms to escape 
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the restriction activity of APOBEC3 proteins. HIV-1 encodes a protein called Vif (virion 
infectivity factor) that can bind to APOBEC3 proteins, and determine their degradation through 
the 26S proteasome (18,83). Vif binds the N-terminal region of APOBEC3 and links it to the 
ubiquitin ligase (E3) complex. This complex will consequently promote the polyubiquitylation of 
APOBEC3 and its subsequent degraded by the proteasome (3,18). In the absence of Vif, hA3G 
acts to inhibit retroviral replication by mechanisms other than deamination. It is has been 
proposed that the RNA binding domain of CD1 physically interacts with the RT and inhibits the 
infectivity of the virus without editing any residues on the single stranded DNA intermediate (3, 
18,19,25,60). Furthermore, as discussed below, MuLVs have evolved mechanisms to evade the 
actions of mA3 not involving cytosine deamination. 
A3 enzymatic activity is closely regulated to protect the cell’s genomic DNA from APOBEC3 
catalytic activity during cell division (18). A3 proteins are generally localized in the cytoplasm; 
however, some family members like hA3B reside in both the cytoplasm and nucleus (18). 
Depending on the current activation status of the cell, A3 proteins either form 5-15 MDa high 
molecular mass (HMM) ribonucleoprotein complexes or 150 kDa low molecular mass (LMM) 
ribonucleoprotein complexes (18). It is possible that some retroviruses may exploit these 
mechanisms to circumvent the actions of A3 proteins.  
 
1.5.2. Murine APOBEC3 (mA3) 
There is only one A3 gene in the mouse genome and is situated on mouse chromosome 
15. This is in contrast to the seven A3 genes in humans. (18). mA3, like hA3G, has two catalytic 
domains however the structural organization and functional roles of the catalytic domains are 
dissimilar than its human counterpart (13,18,50,140). mA3 was reported to have a reversed 
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structural organization compared to the human A3G protein (50). The deaminase activity of mA3 
resides in the CD1 while the RNA binding and encapsulation into the virion resides in CD2 (50). 
Sequence analysis of a variety of mouse strains and species show that mA3 is expressed from 
two major mouse alleles. Different inbred mouse strains express either a C57BL/6 or BALB/c 
mA3 allele (95) that differ by their splicing patterns as well as some polymorphic differences. 
The full-length mRNA transcript of mA3 contains 9 exons and both major mA3 alleles have 
related mRNA splicing isoforms (95). However, two splice variants have been identified for 
mA3 (delta-exon 2 and delta-exon 5) (114,120), and it has been shown that almost all of the 
mRNA transcripts from the C57BL/6 allele exclude exon 5 (over 95%) (13,73,95). In recent 
studies by Santiago et al., it has been show that mA3 is synonymous with Rfv3 (Recovery from 
Friend virus 3) (120); a gene implicated in the resistance of certain mouse strains to the induction 
of acute erythroleukemia in adult mice by the Friend virus complex of the F-MuLV and a 
replication-defective pathogenic virus termed the spleen focus-forming virus (SFFV) (120). 
  
1.5.3. mA3 as retroviral restriction factor 
Many retroviruses and endogenous retroelements are restricted by the cytidine-deaminase 
activity of mA3 (73,79,140). Several studies have also reported that mA3 can partially inhibit the 
replication of exogenous MuLVs such as F-MuLV or M-MuLV although none have been shown 
to exhibit G to A hypermutation with the exception of AKV (119,2,31,46,120,73). AKV MuLV 
was identified as an endogenous ecotropic virus in the thymoma-prone mouse strain AKR (115). 
Although it is endogenous to this mouse strain, it is capable of infecting and replicating as an 
exogenous virus and is susceptible to the cytidine-deaminase activity of mA3 (73).  
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A number of studies have reported that mA3, like hA3G can cause high levels of G→A 
mutations in the HIVΔvif proviral genome. Furthermore, mA3 can also mutate- wild-type HIV-1 
because Vif is not able to interact with murine A3 protein (39,95,153). Conversely, hA3g 
induces high levels of G→A mutations in murine retroviruses however, as noted above, mA3 
does not. 
MuLVs do not encode a Vif like accessory protein, however they have evolved a mechanism(s) 
to evade the action of mA3 (11,13,31,73). Very recent studies have reported that MuLV glyco-
Gag is involved it the resistance to mA3 during the retroviral replication (68,92,132). It is not 
completely clear how mA3 is able to restrict MuLVs, and why in some cases, the inhibition 
proceeds by a deaminase-independent mechanism and in others with a deaminase-dependent 
mechanism (18,19,79,94,140). 
One of major aims of the current studies is to elucidate mechanisms by which mA3 is able to 
inhibit the replication of MuLVs. Studies have focused on the inhibition of MuLVs by 
deaminase-independent mechanisms of mA3 as well as the inhibition of AKV by a deaminase-
dependent mechanism. 
1.6. Importance of the work  
These studies focus on understanding how mA3 influences MuLV replication. The 
APOBEC proteins are found throughout the mammalian system and are important in many 
physiological processes such as the maturation of immunoglobulins, as well as the control of 
retroviral endogenous elements. In addition they serve as part of the innate immune system to 
protect hosts against exogenous retrovirus infection. The mechanisms employed by the APOBEC 
proteins to protect against retrovirus infection are varied as are the mechanisms evolved by 
retroviruses to circumvent these defenses. A thorough understanding of the interplay between 
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these factions in different systems may facilitate the development of intervening pharmaceuticals 
against retroviral infection such as HIV or HTLV in humans. Further, some MuLVs are capable 
of infecting the human population. In this regard, proliferative diseases in humans have been 
attributed to MuLV infection acquired during gene therapy trials (49). A thorough knowledge of 
factors that may influence this interspecies infection are critical for anticipating possible 
consequences.  
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Chapter 2: Incorporation of mouse APOBEC3 into MuLV virions decreases 
the activity and fidelity of reverse transcriptase 
 
Part of the data reported in this chapter have been submitted to Journal of Virology: 
Stefano Boi, Angelo Kolokithas, Joyce Shepard, Rebbeca Linwood, Kyle Rosenke, Erik 
VanDis, Frank Malik and Leonard H. Evans. Incorporation Of Mouse APOBEC3 Into MuLV 
Virions Decreases The Activity And Fidelity Of Reverse Transcriptase. J Virol. Sub. Feb 10 
2014 
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2.1. Introduction 
APOBEC3G (hA3G) in humans and APOBEC3 (mA3) in mice are cytidine deaminases 
that act on single-stranded DNA during reverse transcription resulting in G→A hypermutation of 
newly synthesized proviral DNA (18,73). Although APOBEC3 family members from both hu-
mans and mice inhibit endogenous LTR retrotransposons and retroviruses (11,34,33), exogenous 
murine leukemia viruses (MuLVs) are relatively insensitive to the actions of murine mA3 (2,11, 
13,31,68,73). Several studies, however, have reported partial inhibition of exogenous MuLVs 
after incorporation of mA3 ranging from 10 to ~90% when assayed in vitro 
(2,31,46,73,118,119,120). Furthermore, the finding that Rfv3, a resistance gene for Friend 
erythroleukemia, encodes mA3 and is responsible for a decreased infectious titer of the Friend 
(Fr-) MuLV (120,130,140) strongly suggests that mA3 inhibits the replication of exogenous 
MuLVs in vivo. 
Exogenous ecotropic MuLVs such as the Fr-MuLV and Moloney (Mo-) MuLV are inhibited 
through mechanisms that do not appear to involve cytidine deamination (46,73,102). In contrast, 
the ecotropic MuLV, AKV, isolated from AKR mice has been reported to undergo G→A hy-
permutation after virion incorporation of mA3 (73). In an earlier report (68) we found that the 
infectivity of CasFrKP, an ecotropic MuLV which induces a rapid neurological disease in suscep-
tible mice, was not significantly inhibited by mA3 incorporated into virions harvested from an 
mA3-expressing cell line. However it was not known how the levels of mA3 incorporation in our 
experimental protocol compared to the levels achieved by co-transfection of cells with plasmids 
encoding mA3 and plasmids encoding MuLVs; a protocol commonly employed in in vitro stud-
ies of mA3 and MuLVs (11,13,18,46,68,118). In the present study we have examined the infec-
tivity of CasFrKP released from cells expressing varying levels of mA3. We have observed that a 
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higher level of mA3 incorporation does indeed result in a loss of infectivity which is accompa-
nied by a significant loss of virion reverse transcriptase (RT) activity. Moreover, although G→A 
hypermutation was not observed, we found a highly significant increase in the overall mutation 
rate of CasFrKP in the presence of mA3, reflecting a decrease in the fidelity of the enzyme. It 
seems probable that the loss of activity and fidelity of RT facilitates the observed loss of infectiv-
ity. It is likely that the inhibitory action of mA3 is a result of interaction of the restriction factor 
with the viral polymerase. 
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2.2. Materials and Methods 
2.2.1. Plasmids, cells and viruses. 
The plasmid encoding the full length mA3 derived from the BALB/c mouse strain was a 
kind gift from Dan Littman (13). It was provided in the pcDNA3 vector and was tagged at the C-
terminus with hemagglutinin (HA) (83). NIH 3T3 (3T3) were maintained in Dulbecco’s modi-
fied Eagle medium with 10% bovine serum and penicillin/streptomycin. Quantitative RT PCR 
assays using the forward primer (ACCTGAGCCTGGACATCTTCA), the reverse primer 
(TGCAAAGATTCTGCTGGTTTTC) and the FAM-TAMRA probe (TCCCGCCTC-
TACAACATACGGGACC) revealed that mA3 RNA was below the level of detection in 3T3 
cells (data not shown). Plasmid DNA encoding mA3 was transfected into 3T3 cells using 
lipofectamine (Life Technologies) according to the manufacturer’s instructions and selected in 
media containing 1 mg/ml G418. Single colonies of cells were transferred to new dishes and 
tested for the expression of the C-terminal HA-tagged mA3 construct after ten passages. Cells 
stably expressing the C-Terminal HA-tagged mA3 construct (3T3mA3) were maintained in se-
lection media. CasFrKP is a MuLV derived from the wild mouse ecotropic virus CasBrE and con-
tains a short sequence of the F-MuLV, FB29 (106).  
2.2.2. Immunoblotting 
Cellular mA3 levels were determined in lysates prepared using the CelLytic M Cell Lysis 
Reagent (Sigma). Cell lysates were centrifuged at 20,000 x g for 10 minutes to separate the solu-
ble and insoluble fractions. The protein concentration of the soluble fraction was determined us-
ing a Bradford assay (Pierce) according to the manufacturer’s protocol. Samples were normal-
ized according to their protein concentrations and were adjusted to 1X Laemmli sample buffer 
containing 5% β-mercaptoethanol and boiled for 10 minutes. The samples were then subjected to 
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SDS-PAGE (10% acrylamide, Life Technologies), followed by transfer onto PVDF membranes. 
Western Blot analysis was performed using a monoclonal anti-HA horseradish peroxidase 
(HRP)-conjugated antibody (Roche). 
Immunoblots to detect virion p30 were performed on virions sedimented from the virus stocks in 
a Beckman SW 50.1 rotor for 1 hr at 50000 rpm. The pelleted virions were resuspended in TSE 
(100 mM NaCl, 10 mM Tris HCl, 1 mM EDTA, pH 7.5), adjusted to 1X Laemmli sample buffer 
containing 5% β-mercaptoethanol, boiled for 10 minutes, electrophoresed and transferred to 
PVDF membranes as described above. Immunoblots were performed utilizing a monoclonal an-
tibody R187 to p30 (17) directly conjugated to horseradish peroxidase with the Lightning-Link 
HRP Antibody Labeling Kit (Novus Biologicals). Virion p30 on immunoblots was quantified 
using the ImageJ software (122). 
 
2.2.3. Specific infectivity and RT activity 
The infectivity of virions released during an 8 hr interval from mA3 expressing cells as 
well as from cells not expressing mA3 was assessed by a focal immunofluorescence assay (FIA) 
(128). The specific infectivity’s of virions in the samples were compared by normalizing the in-
fectivity to the levels of the p30 capsid (CA) protein, the major structural protein of the virion. A 
portion of each sample was also assessed for RT activity using the Reverse Transcriptase Assay, 
colorometric (Roche Applied Science) according to the manufacturer’s instructions and normal-
ized to the quantity of virions in the samples assessed by the level of p30. 
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2.2.4. Mutational Analyses 
The effect of virion-associated mA3 on the mutation of viral transcripts was assessed in 
NIH 3T3 cells infected with viruses harvested from 3T3 cells or from 3T3 cells expressing mA3 
(3T3mA3). We derived clonal cell lines after infection of 3T3 or 3T3mA3 cells with the exoge-
nous ecotropic MuLV CasFrKP at a low multiplicity of infection as previously described (88). 
This served to minimize the initial genetic heterogeneity of the virus as well as to obtain infected 
clonal cell lines expressing varying amounts of mA3. Mutation rates were assessed after infec-
tion of 3T3 cells with virus harvested from 3T3 cell lines or from 3T3/mA3 cell lines expressing 
varying levels of mA3. Eight hours after infection cellular DNA was isolated using the Aqua-
Genomic DNA isolation kit (Aquaplasmid) according to the manufacturer’s instructions. Viral 
DNAs synthesized during the first eight hours of infection were amplified by PCR using Pfx50 
polymerase (Life Technologies). Primers specific for different regions of the CasFrKP genome 
included primers near the gag gene (CasFrKP0234, GTCCATTGTCCTGTGTCTTT-
GATTGATTTTA as the forward primer and CasFrKP1193RC, ATTGGGGAGGGATCCGGTG 
as the reverse primer): within the pol gene (CasFrKP3592, GTCCAGACCAGCAAAAAGCCTT 
as the forward primer and CasFrKP4687RC, AAGTGGCTCCTAGTTTGGTCAAATC as the 
reverse primer) and within the env gene (CasFrKP6805, TTGAGAGAGTACACTAGTC as the 
forward primer and CasFrKP7886RC, TCTGTTCCTGACCTTGATC as the reverse primer). 
PCR products were resolved on a 3% 3:1 NuSieve agarose gel and were purified using a Zymo-
clean Gel DNA Recovery kit (Zymo research) according to the manufacturer’s instructions. Puri-
fied PCR products were cloned using the Zero Blunt TOPO PCR Cloning Kit for Sequencing 
(Invitrogen) according to the manufacturer’s instructions. Transformed colonies were isolated 
from selective LB agar plates containing 50 µg/ml Kanamycin and the selected colonies were 
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grown in 1 ml Kanamycin-containing medium. Their DNA was purified with an Extract-N-
Amp™ Tissue PCR Kit (Sigma) according to the manufacturer’s instructions. DNA from indi-
vidual cultures were screened by PCR to confirm the presence of the appropriately sized insert 
and the PCR products from 96 confirmed clones were purified with a QIAquick 96 PCR Purifi-
cation Kit (Qiagen) and sequenced using the primers used to generate the amplicons. 
In experiments comparing the mutation rates in different regions of the genome, the DNAs iso-
lated from cells 8 hours after infection were amplified using GE Healthcare Ready-to-go beads 
(Cat # 27-9559-01) according to the manufacturer’s protocol. Amplicons were then cloned into 
the PCR4-TOPO vector using the TOPO TA Cloning Kit for Sequencing (Invitrogen) according 
to the manufacturer’s instructions. Transformed colonies were isolated on selective LB agar 
plates contain 250 µg/ml carbenicillin, their DNAs purified, screened and sequenced as de-
scribed above. Mutation rates for the different regions of the genome were corrected for back-
ground levels of mutation by the Taq PuRe polymerase. Background levels were determined by 
sequencing amplicons of plasmid DNA encoding the CasFrKP provirus which exhibits minimal 
genetic heterogeneity. 
Groups of sequences generated in these analyses were compiled and compared in the DNAstar 
Lasergene program, SeqMan. Mutation rates for each type of point mutation (e.g., G-to-A transi-
tions) were calculated as the frequency per nucleotide of that type of mutation in each sequenced 
clone. The mutation rates for each type of mutation for each clone were averaged to give the 
mean mutation rate as well as the standard error for that specific type of mutation. The overall 
mutation rate per clone was calculated as the frequency per nucleotide of all mutations in each 
clone. The overall mutation rate for the data set was calculated by averaging the rate for each 
clone to give the mean overall mutation rate and the standard error. 
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2.2.5. Statistical analysis 
The significance of differences between mutation rates was calculated by one way 
ANOVA. Probability values <0.05 were considered significant. The significance of the sequence 
preference of bases near mutation sites was calculated by the two-tailed Binomial Test with 
probability values of <0.05% considered significant. All statistical tests were computed using 
GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com. 
  
34 
 
2.3. Results 
2.3.1. Incorporation of mA3 into CasFrKP virions reflects the level of mA3 expression in 
cells 
Previous studies examining the effect of virion incorporation of mA3 have utilized co-
transfection of 293T cells with plasmids encoding MuLVs and plasmids encoding mA3 
(11,13,18,46,73,118). In a recent report we did not observe an influence of virion-associated 
mA3 on the infectivity of CasFrKP (68). However, is was not clear if the level of expression and 
incorporation into virions was similar in our analyses using mouse cells expressing mA3 to those 
using co-transfection of human cells. In this regard, it has been reported that the level of mA3 
correlates with the inhibition of infectivitiy (119). In order to examine the effects of different 
levels of mA3 incorporated into MuLV virions we derived clonal cell lines infected with CasFrKP 
at a low multiplicity of infection such that only 1 to 5% of the clonal lines were infected (88). 
This procedure served to minimize virion genomic heterogeneity as well as yield clones express-
ing different levels of mA3 (Fig. 7). CasFrKP-infected clonal lines selected for study included an 
NIH 3T3 cell line which does not express mA3, 3T3/CasFrKP, as well as two infected clonal cell 
lines expressing different levels of HA-tagged mA3 designated 3T3mA3/CasFrKP-1 and 
3T3mA3/CasFrKP-2 (Fig. 7). The level of virion incorporation of mA3 into the clones infected 
with CasFrKP was lower in the virions released from 3T3mA3/CasFrKP-1 which expresses a low-
er level of mA3 (Fig. 7). These results are consistent with previous studies in which the level of 
transfected plasmid encoding mA3 corresponded to the level of virion incorporation 
(13,118,119). 
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Figure 7. Incorporation of mA3 into virions released from clonal cell lines. The expression of mA3-HA in the 
clonal cell line, 3T3mA3/CasFrKP was determined from an immunoblot of a cellular extract containing 15 
µg protein and developed using an anti-HA monoclonal antibody. Virion mA3-HA released from 
3T3mA3/CasFrKP cells was determined from an immunoblot of a gel of virion proteins contained in 1.5 mls 
of culture supernatant using the anti-HA antibody while virion p30 was determined from immunoblots of 
gels of virion proteins contained in 0.075 mls of culture supernatant developed with a monoclonal anti-
body to p30. Exposure times for the immunoblots of virion p30 were 1 hour while immunoblots of virion 
mA3-HA were exposed for 5 minutes. Parallel analyses of 3T3/CasFrKP cells and virions, devoid of mA3-HA 
were included as a controls 
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2.3.2. Virion associated mA3 suppresses MuLV infectivity 
The infectivity’s of CasFrKP harvested from the two mA3-expressing clonal cell lines, 
3T3mA3/CasFrKP-1 and 3T3mA3/CasFrKP-2, was compared to CasFrKP harvested from NIH 3T3 
cells not expressing mA3, 3T3/CasFrKP. Reverse transcriptase (RT) activity has frequently been 
used to normalize infectivity to virion particles (2,11, 46,102,118,119,120). However, several 
studies have implicated RT as a possible target of APOBEC3 proteins (9,83,132,143) suggesting 
that RT activity may be misleading with regard to MuLV specific infectivity. In these studies, we 
have normalized the infectivity of the viruses using the level of the capsid protein (CA, p30) 
which is the major structural protein of MuLVs and easily detected by immunoblotting proce-
dures. We found that the specific infectivity of virions released from cells expressing mA3 was 
significantly diminished compared to virions released from cells devoid of mA3 (Fig. 8). Fur-
thermore, the degree of inhibition correlated with the level of mA3 in the virions (Figs 7 and 8). 
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Figure 8. Suppression of infectivity by virion-incorporated mA3. The infectivity’s of virions released from 
cells during an 8 hour interval were determined by the FIA and normalized to the levels of p30 present in 
the samples. The determinations are expressed as a percentage of the mean specific infectivity exhibited 
by virions released from cells not expressing mA3 (3T3/CasFrKP). Error bars represent the standard error 
of 3 to 6 determinations. Significant differences determined by one way ANOVA are indicated (**** 
P<0.0001, *** P>0.0001 to 0.001, *P>0.001 to 0.01). Parallel analyses of 3T3/CasFrKP cells and virions, 
devoid of mA3-HA were included as a controls. 
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2.3.3. Decrease in RT activity by virion-incorporated mA3 
A change in the efficiency of reverse transcription may reflect an interaction of mA3 with 
RT and contribute to the loss of infectivity observed in virions that have incorporated mA3. To 
examine this possibility we determined the RT activity in virions containing different levels of 
mA3 and normalized the activity to the virion p30 (Fig. 9). As was the case with infectivity, the 
RT activity was significantly lower in 3T3mA3/CasFrKP-1 and 3T3mA3/CasFrKP-2 than in 
3T3/CasFrKP and correlated with the level of virion mA3.  
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Figure 9. Supression of RT activity by virion-incorporated mA3. The RT activity of virions released from cells 
during an 8 hour interval were determined and normalized to the levels of p30 present in the samples. RT 
activity was determined for virions contained in 2.5 mls of supernatant media of the samples assayed for 
infectivity in Fig. 1. The determinations are expressed as a percentage of the mean specific infectivity 
exhibited by virions released from cells not expressing mA3 (3T3/CasFrKP). Error bars represent the 
standard error of 3 to 7 determinations. Significant differences determined by one way ANOVA are 
indicated (**** P<0.0001, *** P>0.001 to 0.01). 
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2.3.4. Incorporation of mA3 into virions results in a decrease of RT fidelity 
One of the mechanisms of retroviral inhibition by APOBEC3 proteins, including mA3 
and human APOBEC3G (hA3G), is through deamination of C→U in newly transcribed single 
stranded DNA resulting in G→A hypermutation upon subsequent DNA replication. Although 
most studies examining the effect of mA3 on MuLVs have not revealed hypermutation, one 
MuLV (AKV) has been reported to be susceptible to hypermutation by mA3 (68). Single strand-
ed DNA containing U can be degraded through the action of enzymes such as uracil DNA glyco-
sylase and apurinic endonuclease (70,123,147) and considerable degradation may occur before 
integration of the provirus (81,82) masking the extent of hypermutation. Therefore we isolated 
and examined RT transcripts after only 8 hours of infection to determine the rates of mutation. 
NIH 3T3 cells were infected with viruses harvested from each of the three clonal cell lines 
(3T3/CasFrKP, 3T3mA3/CasFrKP-1 or 3T3mA3/CasFrKP-2), and total cellular DNA was isolated. 
Newly synthesized transcripts were amplified using virus-specific primers from the env gene. 
The amplicons were gel purified, subsequently cloned and transformed into E-coli. Approxi-
mately 90 bacterial colonies encoding individual amplicons were selected from each of the viral 
infections and their nucleotide sequences determined. 
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In agreement with other reports (2,31,46,73,118,119,120), analyses of the mutations incurred in 
the transcripts did not reveal a significant increase in G→A mutations attributed to mA3 after 
infection by either 3T3mA3/CasFrKP-1 or 3T3mA3/CasFrKP-2 compared to 3T3/CasFrKP (Fig. 
10). Transversion mutations were infrequent, however increases in transition mutations other 
than G→A mutations were observed. Notably A→G mutations were significantly higher in in-
fections by one of the mA3-containing viruses. C→T and T→C mutations appear elevated but 
the differences between the rates observed in mA3-containing viruses and 3T3/CasFrKP did not 
reach significance (P < 0.05).  
 
Figure 10. Influence of mA3 on individual mutations. 3T3 cells were infected with viruses released from 
each of the clonal cell lines and the nucleotide sequences of env gene transcripts synthesized during the 
first 8 hours were determined. The rates of all transition and transversion mutations are shown. Error 
bars represent the standard error of detected mutations on approximately 90 transcripts from each of 
the infections totaling about 85,000 bases analyzed for each virus. Significant differences determined by 
one way ANOVA are indicated (* P>0.01 to 0.05). 
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Although only the A→G mutations were significantly different between the mA3-containing vi-
ruses and 3T3/CasFrKP, the inclusion of all of the mutations to calculate overall mutation rates 
yielded very significant differences (Fig. 11). Interestingly, viruses released from the two mA3-
expressing clones did not exhibit significant differences between overall or individual mutation 
rates after infection. 
 
Figure 11. Influence of mA3 on the overall mutation rate. The rates of all transition and transversion 
mutations shown in Fig. 10 were combined to calculate the overall mutation rates. Error bars represent 
the standard error of detected mutations on approximately 90 transcripts from each of the infections 
totaling about 85,000 bases for each virus. Significant differences determined by one way ANOVA are 
indicated (*P>0.001 to 0.01). 
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A bias in the mutation rate in retroviruses has been reported in which the frequency of incurred 
mutations differs in different regions of the viral genome (16,107,153). In addition to the env 
gene amplicons, we examined the mutation rates in amplicons generated by primers specific to 
the pol gene as well as the gag-5’LTR region for mA3-containing virions. A significant differen-
tial effect of mA3 in different regions of the genome was not observed (Fig. 12). 
 
Figure 12. Effect of mA3 on mutation rates of different regions of the viral genome. Mutation rates were 
determined for transcripts from different regions of the viral genome obtained 8 hours after infection of 
cells with viruses from the 3T3mA3/CasFrKP-2 clonal cell line. The schematic depicts the viral genome and 
coordinates of the sequences included in the analysis. Bars in the graph represent mutation rate +/- the 
SEM detected on approximately 90 transcripts totaling about 85,000 bases from each region. 
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2.3.5. Sequence context of mutations effected by mA3 in CasFrKP 
G→A mutations induced by mA3 exhibit a consensus of two 3’-flanking A residues cor-
responding to a preferred target sequence of 5’ TTC on newly synthesized minus strand tran-
scripts for the cytidine deaminase activity (11,62,73,102). In the present study, very significant 
increases in transition mutations other than G to A transitions were observed. It was of interest to 
examine the flanking sequences of these mutations to determine if any sequence consensus was 
evident. The mutation rates of the transcripts of viruses from the two mA3-expressing clones 
were not found to be significantly different, thus mutations from both were included in these 
evaluations. The analyses revealed only four instances of flanking sequences that were signifi-
cantly different from the expected frequency of bases (Fig. 13). A→G transitions had significant-
ly elevated A residues at positions +1 and +2, G→A transitions exhibited a significantly elevated 
incidence of G at the +1 position compared to the expected frequency, while T→C transitions 
exhibited a significantly elevated incidence of C at the -1 position. 
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Figure 13. Consensus 3’ and 5’ sequences of mA3-induced transition mutations. The incidence of flanking 
bases for each of the transition mutations observed in transcripts obtained 8 hours after infection by 
mA3-containing viruses is shown. Analyses include mutations detected in approximately 180 transcripts 
totaling about 170,000 bases. Significant elevation of the frequency of bases at each position compared 
to the expected frequency was calculated by the two-tailed Binomial Test with probability values of 
<0.05% considered significant (*** P>0.0001 to 0.001, **P>0.001 to 0.01, *P>0.01 to 0.05). 
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2.4. Discussion 
MuLVs have evolved mechanism(s) to evade the action of mA3 however numerous stud-
ies have reported partial inhibition of infectivity by the restriction factor ranging from 10 to 
~90%. In an earlier study we reported that CasFrKP virions released from cells expressing mA3 
did not exhibit a loss of infectivity (68). In that study infectivity was normalized to the level of 
RT activity in the infectious virus stocks; a frequently employed criterion for calculations of spe-
cific virion infectivity (2,11,46,102,118,119,120). In this study we normalized both infectivity 
and RT activity to the level of virions by quantifying p30, the major structural protein of the vi-
rus. We found that both the specific infectivity and the RT activity per virion were significantly 
decreased in the presence of mA3. Thus, normalization to RT activity in our earlier study may 
have resulted in an underestimation of the number of virions and an overestimation of the specif-
ic infectivity. Further, previous reports of suppression of infectivity by mA3 have utilized virions 
released from human 293T cells after co-transfection with plasmids encoding mA3 and plasmids 
encoding MuLV proviruses (2,11,46,102,118,119,120). It is possible that co-transfection proce-
dures yield higher levels of virion-incorporated mA3 than was achieved in our earlier study. In 
the present report we selected clones of CasFrKP-infected cells expressing higher levels of mA3. 
A decrease in the specific activity of RT in virions after incorporation of mA3 was observed. 
Several studies have implicated RT as a possible target of APOBEC3 proteins (9,83,132,146), 
however few of these studies have investigated if virion-incorporated mA3 influences the effi-
ciency of reverse transcription in cell-free reactions. One recent study reported a decrease in the 
strong-stop DNA, the initial product of reverse transcription, synthesized by mA3-containing 
virions in endogenous RT reactions (132). A decrease in strong-stop DNA may reflect an inhibi-
tion of an early step in the replication of the genome rather than an actual decrease in the tran-
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scriptional activity of the enzyme. Similarly, another report proposed an effect of hA3G on the 
elongation of HIV-1/Δvif transcripts in reactions utilizing cell-free virions (9). It was suggested 
that this activity may contribute to the inhibition of HIV-1 infection and may be the result of ste-
ric hindrance of the HIV RT by binding of the hA3G to HIV RNA rather than a direct interaction 
with the RT. In the present study the CasFrKP RT activity was assessed using exogenous pol-
yA/oligo dT as the substrate/primer. It seems more likely that the inhibition observed resulted 
from an interaction of mA3 with the RT and a decrease in the inherent transcriptional activity 
rather than steric inhibition of mA3 bound to the virion RNA. 
Significant differences in G→A mutation rates were not observed in mA3-containing CasFrKP 
compared to CasFrKP devoid of mA3, in agreement with other reports of mA3-inhibition of 
MuLVs (2,31,46,73,118,119,120). However, very significant increases in overall mutation rates 
were observed, largely as a result of other transition mutations. G→A mutations mediated by 
mA3 have been reported to exhibit a strong consensus of two 3’ flanking A residues correspond-
ing to a 5’ TTC consensus in the reverse transcribed single stranded DNA; the preferred target of 
mA3 cytidine deaminase activity (11,62,73,102). A paucity of target sequences in CasFrKP could 
reflect the low G→A mutation rate. In contrast to other MuLVs, G→A hypermutation mediated 
by mA3 has been reported for the ecotropic AKV from AKR mice. A comparison of putative 
mA3 target sequences from the AKV genome to those of the CasFrKP sequence did not reveal 
substantial differences in the number of preferred sites (Table 1).  
It has been reported that different regions of the genome undergo different rates of G to A hy-
permutation, notably in a 5’ to 3’ gradient along the transcripts (16,62,140,153). The gradient of 
G to A mutations presumably reflects the exposure of single stranded DNA negative strand tran-
script to the action of the cytidine deaminase activity of mA3. Analyses of the overall mutation 
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rates of different regions of the viral genome including the LTR/gag region the pol region and 
the env region revealed no region that was significantly elevated indicating the absence of hy-
permutation in those regions.   
Although the level of mA3 in the virions released from the two mA3-expressing cell lines were 
dissimilar (Fig. 7), the mutation rates observed in the transcripts from the viruses were not signif-
icant different (Figs. 10 and 11). If mA3 interacts with RT in a stoichiometric manner, the mA3 
level necessary to affect the fidelity of the polymerase may be low and only a small portion of 
the virion-incorporated mA3 may be pertinent to this activity. Indeed, it has been estimated that 
as little as 4 to 7 molecules per virion is sufficient to affect inhibition of infectivity by hA3G 
(147). 
Analysis of the sequence context of the mA3-induced transition mutations considered the two 
adjacent bases both 3’ and 5’ of the mutation. Context analysis of all of the transition mutations 
revealed residues at only four positions whose occurrence was significantly higher than the ex-
pected frequency (Fig. 7). A→G transitions exhibited 3’ adjacent A residues at positions +1 and 
+2, G→A transitions exhibited a 3’ adjacent G at the +1 position while T→C transitions exhibit-
ed a 5’ adjacent C at the -1 position. The relevance of these differences to the mutagenic activity 
of mA3 is unknown, however it is clear that the context of the G to A mutations of CasFrKP 
(GGN) is distinct from that observed with mA3 induced G to A hypermutation (GAA) 
(11,62,73,102) and is unlikely to involve cytidine deaminase activity. 
The results of this study revealed a direct effect of virion-incorporated mA3 on the RT of the vi-
rus which affects the rate of the transcription process as well as the fidelity of the enzyme. These 
results suggest a direct interaction of mA3 with the RT that facilitates a marked loss of infectivi-
ty. A loss of fidelity of RT as a result of mA3 incorporation has not been previously reported and 
49 
 
may represent another cytidine deaminase-independent mechanism by which APOBEC proteins 
act to inhibit retroviral replication. 
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TABLE 1. Putative mA3 target sequences of CasFrKP and AKV1 
 
MuLV C (%) TC (%) TTC (%) 
CasFrKP   2050 (24.9%) 2 593 (7.2%) 149 (1.7%) 
AKV 2055 (25.5%) 585 (7.0%) 148 (1.8%) 
 
1Target sequences for mA3 cytidine deaminase sites were compiled from the com-
plementary sequences of the MuLVs. 
2The sequence of CasFrKP was deduced from the sequences of the two parental 
MuLVs, CasBrE and FB29 (accession nos. X57540and Z11128, resp.). The AKV 
sequence is from (accession no. J01998). 
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Chapter 3: The ecotropic AKV MuLV undergoes G→A hypermutation inde-
pendent of augmented APOBEC3 
 
3.1. Introduction 
Mouse APOBEC3 (mA3) is a cytidine deaminase that acts on single-stranded DNA dur-
ing reverse transcription by murine retroviruses resulting in G→A hypermutation of newly syn-
thesized proviral DNA (18,73). Although mA3 inhibits endogenous retroviruses (35), exogenous 
murine leukemia viruses (MuLVs) such as Friend (Fr-) MuLV and Moloney (Mo-) do not under-
go G→A hypermutation upon infection in the presence of mA3 (73,2,10,13,31,68). AKV is an 
endogenous ecotropic MuLV isolated from thymoma-prone AKR mice and can be propagated as 
an exogenous ecotropic MuLV (115,116). In contrast to other MuLVs, AKV has been reported 
to undergo G→A hypermutation upon infection in the presence of mA3 (73). The mutations ex-
hibited a strong consensus of two 3’ flanking A residues, GAA, corresponding to TTC in the 
cDNA transcript sequence which is the target of cytidine deamination. In a recent study, we 
found that an MuLV that has incorporated an HA-tagged mA3 (mA3-HA) does indeed exhibit a 
significantly higher level of mutations. However, the mutations incurred in the presence of mA3-
HA corresponded to transition mutations other than G→A. The mutations did not exhibit a 
strong consensus of flanking bases suggesting a loss of fidelity of the reverse transcriptase in-
duced by mA3-HA rather than recognition of a nucleotide target sequence. In this study we have 
examined the mutations incurred by AKV in the presence or absence of mA3-HA. Surprisingly, 
we observed G→A hypermutations in transcripts generated after infection by viruses released 
from cells that did not express mA3-HA. The mutations exhibited a strong consensus of flanking 
bases similar to that reported for mA3. Infection by AKV released from cells expressing mA3-
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HA exhibited a nearly identical G→A mutation rate and consensus of flanking bases. Further-
more, an unequal distribution of mutations was observed such that many of the transcripts exhib-
ited multiple mutations while the majority of transcripts exhibited none. Our studies suggest that 
AKV is very susceptible to an restriction factor endogenous to 3T3 cells that exhibits cytidine 
deaminase activity that is active in only a portion of virions released from cells The observation 
that the incorporation of mA3 did not alter the extent of distribution of the transcripts suggests 
that the restriction factor may be distinct from mA3.  
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3.2. Materials and Methods 
3.2.1. Plasmids, cells and viruses 
The maintenance of cell lines, the derivation of cells expressing mA3 by transfection of 
plasmids and the use of viruses in this study were as described in chapter 2.2.1. In addition AKV 
was derived by transfection of NIH 3T3 cells with the molecular clone 623 (80). 
3.2.2. Immunoblotting 
Immunoblotting procedures were performed as described in chapter 2.2.2. 
3.2.3. Mutational Analyses 
The effect of virion-associated mA3 on the mutation of viral transcripts was assessed in 
NIH 3T3 cells infected with viruses harvested from 3T3 cells or from 3T3 cells expressing mA3 
(3T3mA3). We derived clonal cell lines after infection of 3T3 or 3T3mA3 cells with the exoge-
nous ecotropic MuLV CasFrKP and AKV at a low multiplicity of infection as previously de-
scribed (88). This served to minimize the initial genetic heterogeneity of the virus as well as to 
obtain infected clonal cell lines expressing varying amounts of mA3. Mutation rates were as-
sessed after infection of 3T3 cells with virus harvested from 3T3 cell lines or from 3T3/mA3 cell 
lines. Eight hours after infection cellular DNA was isolated using the AquaGenomic DNA isola-
tion kit (Aquaplasmid) according to the manufacturer’s instructions. Viral DNAs synthesized 
during the first eight hours of infection were amplified by PCR using Pfx50 polymerase (Life 
Technologies). Primers within the env gene of CasFrKP (CasFrKP6805, TTGAGAGAGTACAC-
TAGTC as the forward primer and CasFrKP7886RC, TCTGTTCCTGACCTTGATC as the re-
verse primer). Viral DNAs from AKV-infected cells were amplified using AKV env-specific 
primers (AKV 6899 CACAAATTGACCTTGTCCG as the forward primer, AKV 7964RC 
CCCGGTACTTTCCAGCC as the reverse primer). PCR products were resolved on a 3% 3:1 
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NuSieve agarose gel and were purified using a Zymoclean Gel DNA Recovery kit (Zymo re-
search) according to the manufacturer’s instructions. Purified PCR products were cloned using 
the Zero Blunt TOPO PCR Cloning Kit for Sequencing (Invitrogen) according to the manufac-
turer’s instructions. Transformed colonies were isolated from selective LB agar plates containing 
50 µg/ml Kanamycin and the selected colonies were grown in 1ml Kanamycin-containing medi-
um. Their DNA was purified with an Extract-N-Amp™ Tissue PCR Kit (Sigma) according to the 
manufacturer’s instructions. DNA from individual cultures were screened by PCR to confirm the 
presence of the appropriately sized insert and the PCR products from 96 confirmed clones were 
purified with a QIAquick 96 PCR Purification Kit (Qiagen) and sequenced using the primers 
used to generate the amplicons. 
Groups of sequences generated in these analyses were compiled and compared in the DNAstar 
Lasergene program, SeqMan. Mutation rates for each type of point mutation (e.g., G-to-A transi-
tions) were calculated as the frequency per nucleotide of that type of mutation in each sequenced 
clone. The mutation rates for each type of mutation for each clone were averaged to give the 
mean mutation rate as well as the standard error for that specific type of mutation. The overall 
mutation rate per clone was calculated as the frequency per nucleotide of all mutations in each 
clone. The overall mutation rate for the data set was calculated by averaging the rate for each 
clone to give the mean overall mutation rate and the standard error.   
3.2.4. Statistical analysis 
Statistical analysis were performed as described in chapter 2.2.5. 
  
55 
 
3.3. Results 
3.3.1. AKV undergoes G→A hypermutation in NIH 3T3 cells in the absence of mA3-HA 
expression. 
AKV has been reported to undergo G→A hypermutation upon incorporation of mA3 into 
virions. We have recently observed that another MuLV (CasFrKP) does not undergo G→A hy-
permutation upon incorporation of mA3 but rather, undergoes a loss of RT activity as well as a 
loss of fidelity of the enzyme as evidenced by a significant increase in transition mutations other 
than G→A. In order to study the differences between the two MuLVs with regard to their inter-
actions with mA3, we wished to obtain baseline mutation rates of both viruses in the absence of 
mA3. Clonal NIH 3T3 cell lines infected at a low multiplicity of infection (MOI) with either 
AKV or CasFrKP were established and viruses released from the lines were used to infect new 
NIH 3T3 cell lines. Viral DNA transcripts synthesized during the intitial 8 hours after infection 
were amplified by PCR, the amplicons cloned and subsequently sequenced. These analyses re-
vealed a marked difference in the patterns of mutations observed between the two MuLVs (Fig. 
14A). The G→A mutation rate of AKV was much higher than the G→A mutation rate of Cas-
FrKP resulting in a significantly higher overall mutation rate for AKV (Fig. 14B).   
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Figure 14. Mutation rates of AKV and CasFrKP MuLVs in the presence or absence of mA3-HA. Mutations 
incurred in transcripts of AKV or CasFrKP at 8 hr post-infection were determined. A) CasFrKP and AKV in-
dividual mutation rates in the absence of mA3 for each of the possible point mutations. B) Overall (total) 
mutation rates for CasFrKP and AKV in the absence of mA3. C) CasFrKP and AKV individual mutation rates 
in the presence of mA3 for each of the possible point mutations. D) Overall (total) mutation rates for Cas-
FrKP and AKV in the presence of mA3. The bars show the mean and SEM for each rate.  P values were cal-
culated by the students t test with P<0.05 considered significant. 
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3.3.2. G→A hypermutation of AKV is not augmented in the presence of mA3 
Cell lines expressing mA3-HA were infected with AKV or CasFrKP at a low MOI and 
clonal lines were established. Both of the clonal cell lines expressed mA3-HA and both released 
virions that had incorporated mA3-HA (Fig. 15). The level of mA3-HA in the AKV virions ap-
pears to be slightly higher than in the CasFrKP virions even though the expression of mA3 in the 
cells infected with CasFrKP was higher than that expressed by cells infected with AKV. 
The mutation frequencies of mutations upon infection of 3T3 cells by the viruses released from 
each of the mA3-HA clonal cell lines was determined (Fig. 14C). In agreement with our earlier 
observations (submitted for publication) the mutation rates for transition mutations other than 
G→A transitions were elevated resulting in a significant change (P=0.0072) in the overall muta-
tion rate of CasFrKP (Fig. 14B and 14D). In contrast, AKV did not exhibit significant changes in 
mutation rates upon incorporation of mA3-HA. Indeed, the overall mutation rates of AKV and 
CasFrKP were not significantly different in the presence of incorporated mA3 (Fig. 14D). 
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Figure 15. Immunoblots of 3T3, 3T3/AKV and 3T3mA3 cell and virions. The expression of mA3-HA in the 
clonal cell line, 3T3mA3/CasFrKP, 3T3/AKV and 3T3mA3/AKV was determined from an immunoblot of a 
cellular extract containing 15 µg protein and developed using an anti-HA monoclonal antibody. Virion 
mA3-HA released from 3T3mA3 cells was determined from an immunoblot of a gel of virion proteins con-
tained in 1 ml of culture supernatant using the anti-HA antibody while virion p30 was determined from 
immunoblots of gels of virion proteins contained in 0.1 ml of culture supernatant developed with a mon-
oclonal antibody to p30. Exposure times for the immunoblots of virion p30 were 5 minutes while im-
munoblots of virion mA3-HA were exposed for 1 hour.  
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3.3.3. The sequence context of G→A mutations in AKV is similar to the sequence context of 
mA3-induced G→A mutations. 
G→A mutations in AKV as well as other retroviruses susceptible to mA3, e.g., HIV, ex-
hibit a preferred target sequence corresponding to TTC in the negative sense transcript with C 
the base that becomes deaminated (73,10,62,102). Determination of the the sequence context of 
G→A mutations in AKV transcripts observed in the presence and absence of mA3-HA revealed 
a strong consensus target sequence consistent with the cytidine deaminase target of mA3 (Fig. 
16). Indeed, a very conserved consensus sequence flanking the 5’ and 3’ ends of the cytidine tar-
get was observed corresponding to TTCAA in the negative sense transcript. A strong consensus 
flanking both the 5’ and 3’ sides of the cytidine deaminase target has not previously been report-
ed. 
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Figure 16. Consensus target for cytidine deamination of AKV transcripts.  The sequence context of G→A 
mutations in transcripts generated after an 8 hr infection were determined for the two bases flanking the 
3’ and 5’ side of the mutation site. The consensus sequences of the observed G→A mutation as well as 
the consensus of the (–)strand DNA flanking the cytidine deaminase target C residue are shown. Signifi-
cance of the frequency of flanking based was calculated by the two-tailed Binomial Test (**** P<0.0001).  
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3.3.4. G→A mutations are disproportionate among AKV transcripts 
When compiling the results of the AKV mutations it was noted in both the analyses (in 
the presence or absence of mA3) that the majority of the transcripts were devoid of mutations 
while some of the transcripts exhibited multiple mutations (Tables 3 and 4). In both cases nearly 
100% of the mutations were present in less than 25% of the transcripts.   
The results of these analyses were tabulated and subjected to a chi-square test for compliance to 
a random distribution. It was found that the data were inconsistent with a random distribution of 
mutations with a P value of <0.0001. 
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TABLE 2. Distribution of G→A mutations in 3T3/AKV 
Mutations 
Per Transcript (#) 
% 
Mutations 
%* 
Transcripts 
0 (64) 0 74 
1 (16) 49 19 
2 (2) 12 2 
3 (3) 27 3 
4 (1) 12 1 
*The distribution of G→A mutations in AKV transcripts in the absence of 
mA3 after 8 hrs. of infection are tabulated. The percent of transcripts were 
rounded down resulting in less than 100%. The data are not consistent 
with a random distribution of mutations using a chi-square test with 
p<0.0001. 
 
TABLE 3. Distribution of G→A mutations in 3T3mA3/AKV 
Mutations 
Per Transcript (#) 
% 
Mutations 
%* 
Transcripts 
0 (54) 0 81 
1 (6) 23 9 
2 (3) 23 4 
3 (2) 23 3 
4 (2) 31 3 
*The distribution of G→A mutations in AKV transcripts in the presence of 
mA3 after 8 hrs. of infection are tabulated. The data are not consistent 
with a random distribution of mutations using a chi-square test with 
p<0.0001.  
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3.4. Discussion 
 This investigation was initiated with the aim of comparing the effect of mA3 on two 
MuLVs that have been reported to be inhibited by two distinct mechanisms. AKV has been re-
ported to undergo G→A hypermutation (73) while our studies have established that the MuLV, 
CasFrKP does not undergo G→A hypermutation but rather undergoes a significant inhibition of 
RT activity and an increase in overall mutation rate reflecting a loss of RT fidelity. These find-
ings correlate with a significant loss of infectivity. We unexpectedly found that AKV exhibited 
G→A hypermutation in the absence of detectable mA3 incorporation into virions. Furthermore, 
the incorporation of mA3 into AKV virions did not augment hypermutation of the AKV tran-
scripts. In contrast, Langlois et al., (73) reported that incorporation of mA3 into AKV virions 
resulted in G→A hypermutation. Although the mutation rate of AKV in the absence of incorpo-
rated mA3 was not examined in that study, G→A hypermutation was not observed after incorpo-
ration of human APOBEC2 suggesting that mA3 was necessary for G→A hypermutation of 
AKV.  
The discrepancy between the results reported here and those of Langlois et al., (73) may be the 
result of the levels of mA3 incorporated into the virions as well as the source of the AKV stock. 
In that study AKV stocks were obtained after co-transfection of human cells with a plasmid en-
coding mA3 and a separate plasmid encoding AKV. A much higher level of mA3 incorporation 
could account for their observation that virion incorporated mA3 altered the extent of hypermu-
tation. Our AKV stocks were obtained from infected mouse NIH 3T3 cells or from NIH 3T3 
cells that were expressing HA-tagged mA3. The incorporation of a restriction factor endogenous 
to mouse cells but not to human cells could explain why hypermutation occurred in the absence 
of augmented mA3-HA. A strong sequence consensus for the cytidine deaminase targets was ob-
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served in the  minus strand reverse transcript (TTCAA) suggesting mA3-mediated cytidine de-
amination in agreement with previous studies (18,73,35,2). However a consensus on both the 3’ 
and 5’ flanking sequences has not been previously observed with either mA3 or mouse APO-
BEC1 which has also been reported to restrict MuLVs (2). 
Another pertinent observation was that the distribution of G→A hypermutations was skewed, 
with a small percentage of the transcripts exhibiting all of the mutations. This result is reminis-
cent of the results of Pathak and Temin (99) who noted G→A hypermutation in a small propor-
tion of transcripts of retroviral vectors under investigation. In their studies it was speculated that 
hypermutation was the result of aberrant polymerases in a small proportion of the virions. In the 
present analysis an aberrant polymerase is very unlikely. The AKV virus stocks were obtained 
from clonal cell lines infected at a low multiplicity of infection and should have only one or at 
most a few proviral copies. Moreover, the results were obtained with progeny viruses from two 
independent clonal lines, yet both populations yielded nearly identical distribution patterns. It 
seems more likely that only a portion of the AKV virions released from NIH 3T3 cells have en-
capsulated a cytidine deaminase restriction factor similar or identical to mA3. 
Although we have previously examined NIH 3T3 cells by quantitative PCR and found the level 
of mA3 mRNA to be undetectable, it is possible that a low level of mA3 is expressed and is re-
sponsible for the hypermutation of AKV transcripts we have observed. To investigate this possi-
bility we utilized a newly available antibody to mA3 in immunoblotting procedures. Immunob-
lots of AKV-infected and uninfected 3T3 cells, as well as 3T3 cells expressing mA3-HA were 
developed with an anti-HA antibody and also with the commercial anti-mA3 antibody (Fig. 17).  
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Figure 17. Immunoblots of 3T3, 3T3/AKV and 3T3mA3 cells. Protein extracts from uninfected 3T3 cells, 3T3 
cells infected with AKV (3T3/AKV) and uninfected 3T3 cells expressing an HA-tagged mA3 (3T3mA3) were 
electrophoresed, blotted and developed with a commercially available antiserum to mA3. The membrane 
was stripped and redeveloped with an antibody to HA to detect the HA-labeled mA3 expressed in 
3T3mA3 cells. 
 
 
The anti-HA antibody detected the ~50 kDa protein in the 3T3mA3 sample, as expected, howev-
er the new commercially available mA3 antibody detected a protein of ~70 kDa in all three sam-
ples. Notably, the new antibody did not detect the mA3-HA present in the 3T3mA3 cells. These 
results suggested that the new antibody did not detect the HA-labeled mA3 even though the pep-
tide used to elicit the antibody was encoded by the mA3-HA plasmid. It was conceivable that a 
previously undescribed form of mA3 was expressed in the 3T3 cells and that the epitope in the 
mA3-HA was masked. Alternatively, the new mA3 antibody may simply detect a cross-reactive 
protein present in the cells. To resolve this issue an immunoblot was performed with samples of 
cell extracts, samples of virion preparations and a mock virion preparation from uninfected 3T3 
cells using the putative mA3 antibody (Fig. 18). The ~70 kDa protein was found in all samples 
including the mock virion preparation. Again, the antiserum failed to detect the mA3-HA 
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epitope. These results suggest that the antibody detects a cross-reactive ~70Da protein that is 
present in 3T3 cells and is released into the growth media, possibly as a vesicular element that 
pellets with virions.  
 
 
Figure 18. Immunoblots of cellular protein, virion preparations and mock virion preparations with a com-
mercially available antibody to mA3. Protein extracts from 3T3 cells, 3T3 cells infected with AKV 
(3T3/AKV),  3T3 cells infected with CasFrKP (3T3/ CasFrKP) and uninfected 3T3 cells expressing mA3 
(3T3mA3) as well as virion preparations of AKV, CasFrKP and a mock virion preparation from uninfected 
3T3 cells were electrophoresed, blotted and develped with a commercially available antiserum to mA3. 
 
 
 
In the absence of a reliable reagent to detect endogenous mA3 we are unable to determine if it is 
the incorporation of endogenous mA3 or some other restriction factor into AKV virions that me-
diates the G→A hypermutation of AKV. However, if only trace amounts of mA3 are necessary 
for the hypermutation, it might be expected that even a small amount of mA3-HA incorporation 
would have effected a higher rate of hypermutation as well as elimination of the skew in the dis-
tribution of mutations. This was not observed suggesting that another restriction factor may be 
endogenous to mouse cells. In this regard, additional quantitative PCR experiments utilizing dif-
ferent sets of primers have not detected mA3 mRNA (data not shown). An approach to the reso-
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lution of this problem may be the utilization of knock out mouse cells in which various re-
striction factors have been eliminated. 
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Chapter 4 
4.1. Conclusions  
APOBEC3 proteins are cytidine deaminases that are potent inhibitors of retrovirus repli-
cation. These restriction factors induce G→A hypermutation as a result of deamination of cyti-
dine in the single stranded transcripts generated by reverse transcription during replication. 
Mouse APOBEC3 (mA3) effectively inhibits the replication of endogenous retroelements 
whereas most exogenous murine leukemia viruses (MuLV) are largely resistant to the action(s) 
of mA3. However, several studies have reported significant inhibition of infectivity by virion-
associated mA3 that did not appear to be the result of G→A hypermutation. Recent studies have 
reported that MuLV glyco-Gag is involved it the resistance to mA3 during the retroviral replica-
tion. (68,92,132). It is not completely clear how mA3 is able to restrict MuLVs, and why in some 
cases, the inhibition proceeds by a deaminase-independent mechanism and in others with a de-
aminase-dependent mechanism (18,19,79,94,140,104). 
In this work, we showed that CasFrKP which encodes gGag does exhibit inhibition of infection, 
RT activity and an increase in the overall mutation rate if a sufficient level of mA3 is incorpo-
rated into the virion. However no G to A hypermutation was observed at any level of mA3. 
These results suggest a direct interaction of mA3 with the RT that facilitates a marked loss of 
infectivity. A loss of fidelity of RT as a result of mA3 incorporation has not been previously re-
ported and may represent another cytidine deaminase-independent mechanism by which APO-
BEC proteins act to inhibit retroviral replication. 
In contrast to CasFrKP, AKV, an ecotropic MuLV isolated from AKR mice, has been reported to 
undergo hypermutation mediated by mA3 (73). In this report we confirm that AKV does undergo 
G→A hypermutation upon infection of 3T3 cells, however hypermutation is not augmented in 
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viruses that have incorporated HA-tagged mA3.  Furthermore a strong sequence consensus was 
observed in the  minus strand reverse transcript (TTCAA) suggesting mA3-mediated cytidine 
deamination  in agreement with previous studies (11,62,73,102). However a consensus on both 
the 3’ and 5’ has not been previously observed with either mA3 or mouse APOBEC1 which has 
also been reported to restrict MuLVs (102). Hypermutations were not distributed randomly with 
100% of the G to A mutations found on about 20 to 25% of the transcripts with some individual 
transcripts containing up to 15% of the total G to A mutations. These results suggest that AKV 
virions have incorporated an endogenous cytidine deaminase restriction factor upon release from 
3T3 cells that exerts its activity on only a portion of the virions. This might be the result of in-
corporation of the factor in only a low proportion of virions.  In this regard it has been reported 
that hA3G is able to inactivate target viruses with as little as 4 to 7 molecules per virion. 
4.2. Future Directions 
 The glycosylated gag proteins (gGag) of MuLVs have been implicated in the evasion of 
exogenous MuLVs from the action of mA3. We have shown that mA3 incorporation at 
high levels into virions encoding gGag can result in an inhibition of RT and a decrease in 
the fidelity of the enzyme. It is not known if a similar mechanism is responsible for the 
increased susceptibility of gGag-negative mutant MuLVs to mA3. Investigations of the 
effect of mA3 on the RT of gGag-negative mutants may elucidate this issue.  
 MuLVs are also inhibited by cellular mA3 upon infection by gGag-negative viruses that 
have not encapsulated mA3. It would be of interest to determine if the mechanism of in-
hibition by cellular mA3 is the same as inhibition by virion-associated mA3. Mutation 
studies on these two manners of inhibition may be enlightening.   
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 mA3 appears to inhibit the infectivity of MuLVs by two different mechanisms. G→A 
hypermutations are observed in AKV while other MuLVs such as CasFrKP do not exhibit 
hypermutation. The construction of chimeric viruses between CasFrKP and AKV may de-
fine what regions of the viral genome are responsible for these differences. Chimeras in-
volving the protective gGag encoding regions may be of particular interest. 
 Our current studies suggest that G→A hypermutation of AKV may be mediated by an 
endogenous restriction factor of mouse cells. These studies will be extended to investi-
gate the hypermutation of AKV originating from different cell types including cells of 
different species such as human 293T cells. In addition, hypermutation of AKV originat-
ing from KO mouse cells that do not express various restriction factors will be investigat-
ed.  
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